BioNTech SE and Shanghai Fosun Pharmaceutical (Fosun Pharma) has signed an agreement on Dec 16 to supply mainland China with 100 million doses of their BNT162 mRNA-based Covid-19 vaccine in 2021.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply